Numinus Wellness Inc. logo

Numinus Wellness Inc. (NUMIF)

Market Closed
11 Feb, 20:00
OTC PINK OTC PINK
$
0. 03
+0
+3.33%
Pre Market
$
0. 03
0 0%
19.89M Market Cap
- P/E Ratio
0% Div Yield
31,600 Volume
0 Eps
$ 0.03
Previous Close
Day Range
0.03 0.04
Year Range
0.02 0.1
Earnings results expected in 61 days

Summary

NUMIF closed today higher at $0.03, an increase of 3.33% from yesterday's close, completing a monthly increase of 29.17% or $0.01. Over the past 12 months, NUMIF stock gained 29.17%.
NUMIF is not paying dividends to its shareholders.
The last earnings report, released on Jan 13, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Apr 14, 2025.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
Want to track NUMIF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

NUMIF Chart

FAQ

What Is the Numinus Wellness Inc.(NUMIF) Stock Price Today?

The NUMIF stock price today is $0.03.

What Stock Exchange Does Numinus Wellness Inc. Trade On?

Numinus Wellness Inc. is listed and trades on the OTC PINK.

What Is the Stock Symbol for Numinus Wellness Inc.?

The stock symbol for Numinus Wellness Inc. is "NUMIF".

Does Numinus Wellness Inc. Pay Dividends? What's The Current Dividend Yield?

NUMIF is not paying dividends to its shareholders.

What Is the Numinus Wellness Inc. Market Cap?

As of today, Numinus Wellness Inc. market cap is 19.89M.

What is Numinus Wellness Inc. Earnings Per Share?

The Numinus Wellness Inc. EPS is 0.

What Is the Next Numinus Wellness Inc. Earnings Date?

Numinus Wellness Inc. will release its next earnings report on Apr 14, 2025.

Did Numinus Wellness Inc. had any splits?

No, Numinus Wellness Inc. has never had a stock split.

Numinus Wellness Inc. Profile

Medical Care Facilities Industry
Healthcare Sector
Mr. Payton Nyquvest CEO
OTC PINK Exchange
- ISIN
US Country
- Employees
- Last Dividend
20 May 2020 Last Split
- IPO Date

Overview

Numinus Wellness Inc. is at the forefront of integrating traditional mental health treatments with innovative psychedelic-assisted psychotherapy. With operations spanning across Canada and the United States, Numinus provides a comprehensive suite of services aimed at addressing a broad spectrum of mental health issues. The company distinguishes itself through its multifaceted approach which includes clinical research, a network of clinics in Canada and the U.S., and groundbreaking laboratory services focused on the development and application of psychedelic substances for therapeutic use. Founded in 1964 and headquartered in Vancouver, Canada, Numinus leverages its decades of experience to push the boundaries of mental wellness therapies.

Products and Services

Numinus Wellness Inc. offers a wide range of products and services designed to cater to various aspects of mental wellness and psychedelic-assisted therapy:

  • Clinical Research Operations: This segment provides comprehensive clinical research management services tailored for academic institutions and biotechnology companies. It encompasses the development, execution, and supervision of clinical trials aimed at exploring the therapeutic potentials of psychedelics.
  • Canadian Clinic Network: In Canada, Numinus operates a network of clinics delivering a diverse array of clinical services. These include but are not limited to traditional therapy and counseling, ketamine-assisted therapies specifically for depression, broader psychedelic-assisted therapies, mindfulness programs, virtual psychotherapy services, and neurological care. This holistic approach to mental health care underlines the company's commitment to innovative and accessible treatments.
  • U.S. Clinic Network: Numinus extends its innovative approach to therapy into the United States, where its clinics offer similar psychedelic-assisted therapies. Additionally, services such as transcranial magnetic stimulation, psychiatric and medical model management further diversify the company's portfolio in the U.S., making varied and effective treatments more accessible to a wider audience.
  • Laboratory Services: A pioneering facet of Numinus is its expansive laboratory operations. These encompass the cultivation, production, and extraction of Psilocybe and other psychoactive fungi species. The company is also engaged in the development of proprietary processes and products, controlled psychedelics protocols, and a product development pipeline. These efforts are complemented by an emphasis on safety, efficacy studies, and lab testing services. This robust infrastructure supports the company's research and therapeutic applications, ensuring high standards of quality and innovation.
  • Psychedelic-Assisted Therapy Training Services: Recognizing the need for qualified practitioners in this emerging field of mental health care, Numinus offers specialized training for professionals. This program aims to equip therapists and medical practitioners with the necessary skills and knowledge to safely and effectively conduct psychedelic-assisted therapies, thereby ensuring the highest levels of care and patient outcomes.

Contact Information

Address: 666 Burrard Street, Vancouver, BC, Canada, V6C 2X8
Phone: 833 686 4687